- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04868513
Streptococcus Mutans Reduction Early Mother-infant Transmission
April 27, 2021 updated by: Marine Ortiz Magdaleno, Biochemical and Microbiology Laboratory, Faculty of Dentistry, Autonomous University of San Luis Pot
Enhancing Effect of the Application of 1% Chlorhexidine Varnish With Silane Fluoride and Oral Health Promotion on the Streptococcus Mutans Counts Reduction in Pregnant Women and on Early Mother-infant Transmission
Evidence exists on the vertical transmission of Streptococcus mutans from the mother to her children.
This transmission can be prevented by maintaining maternal oral health during pregnancy.
Study Overview
Status
Completed
Conditions
Detailed Description
The aim of this study was to evaluate the enhancing effect of 1% chlorhexidine varnish together with silane fluoride re-mineralizing varnish and oral health promotion strategy on the reduction of S. mutans counts in saliva of pregnant women and the early mother-infant transmission until the first six months of age of the newborn.
Methods: An open, random clinical trial of parallel groups was performed.
56 pregnant women free of caries were studied prospectively and longitudinally since the third trimester of gestation until 6 months after giving birth, the newborns were also assessed until reaching 6 months of age.
Two groups were formed assigning 28 women to each intervention group.
G-I received 0.1% silane fluoride applied as varnish in each visit.
G-II women's teeth were coated with 0.1% silane fluoride and 1% chlorhexidine.
For the primary culture, CRT Bacteria® system (Ivoclar-Vivadent™) was used for the growth and identification of cariogenic Streptococci.
Identification of S. mutans was performed through PCR.
The DNA of the isolates identified molecularly as S. mutans was used for a second PCR reaction using the arbitrary primer OPA-O2 to determine the homology among the samples of isolated bacteria from the mother-child pair.
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Pregnant women in the third trimester with a normal and healthy pregnancy.
- Ages ranged from 18 to 45 years
- Free of caries (if caries were present, they were treated before enrolling them in the study).
Exclusion Criteria:
-Non-pregnant women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Pregnant women to whom applied silane fluoride
We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) as varnish in all teeth on all faces as a promotion strategy on the reduction of S. mutans.
|
Pregnant women who received 0.1% silane fluoride applied as varnish in the teeth.
Other Names:
|
|
Experimental: Pregnant women to whom applied silane fluoride + 1% chlorhexidine
We applied 0.1% silane fluoride (Fluor Protector, Ivoclar Vivadent AG™) and 1% chlorhexidine (Cervitec, Ivoclar Vivadent AG™), both applied as varnish, with a 1 min interval between applications, in all teeth on all faces, using the standardized technique indicated by the manufacturer as a promotion strategy on the reduction of S. mutans.
|
Pregnant women who received silane fluoride + 1% chlorhexidine applied as varnish in the teeth.
Other Names:
|
|
No Intervention: Children of the pregnant women to whom it was applied silane fluoride
The children not given any intervention, they were only subjected to a microbiological and clinical examination.
|
|
|
No Intervention: Children of the pregnant women to whom it was applied silane fluoride + 1% chlorhexidine
The children not given any intervention, they were only subjected to a microbiological and clinical examination.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Caries prevalence assessment in pregnant womens
Time Frame: Basal measurement, at the beginning of the third trimester of gestation.
|
For this purpose, the Decayed, Missing, and Filled Teeth Index was used to measure the prevalence of caries.
This index is based on in-field clinical examination of individuals by using a probe, mirror and cotton rolls, and simply counts the number of decayed, missing (due to caries only) and restored teeth the number of participants with prevalence of caries will be reported.
|
Basal measurement, at the beginning of the third trimester of gestation.
|
|
Streptococcus mutans levels identified in pregnant womens
Time Frame: Basal measurement, at the beginning of the third trimester of gestation.
|
In this measurement was identified the S. mutans counts in the saliva of pregnant women after the applications of 1% chlorhexidine varnish together with the application of silane fluoride re-mineralizing varnish or only with the application of silane fluoride, was reported the distribution of cariogenic Streptococcus levels in mothers.
|
Basal measurement, at the beginning of the third trimester of gestation.
|
|
Streptococcus mutans levels identified in pregnant womens
Time Frame: Three months after the birth of the child.
|
In this measurement was identified the S. mutans counts in the saliva of pregnant women after the applications of 1% chlorhexidine varnish together with the application of silane fluoride re-mineralizing varnish or only with the application of silane fluoride, was reported the distribution of cariogenic Streptococcus levels in mothers.
|
Three months after the birth of the child.
|
|
Streptococcus mutans levels identified in pregnant womens
Time Frame: Six months after the birth of the child
|
In this measurement was identify the S. mutans counts in the saliva of pregnant women after the applications of 1% chlorhexidine varnish together with the application of silane fluoride re-mineralizing varnish or only with the application of silane fluoride.
Will be reported the distribution of cariogenic Streptococcus levels in mothers.
|
Six months after the birth of the child
|
|
Genotypes of the isolates of S. mutans in pregnant womens.
Time Frame: Three months after the birth of the child.
|
The genotypes describes an organism's complete set of genes, in this study, was determined the homology among the samples of isolated bacteria from the mother-child pair.
The molecular PCR test was implemented for the identification.
Will be reported the % of S. mutans genotypes isolated from the mothers of both groups to the strains isolated from the newborns.
|
Three months after the birth of the child.
|
|
Streptococcus mutans levels identified in childrens
Time Frame: Three months after the birth of the child.
|
In this measurement was identified the S. mutans counts in the saliva of the children.
Will be reported the distribution of cariogenic Streptococcus levels in the children.
|
Three months after the birth of the child.
|
|
Streptococcus mutans levels identified in children
Time Frame: Six months after the birth of the child.
|
In this measurement was identified the S. mutans counts in the saliva of the children.
Will be reported the distribution of cariogenic Streptococcus levels in the children.
|
Six months after the birth of the child.
|
|
Genotypes of the isolates of S. mutans in children.
Time Frame: Three months after the birth of the child.
|
The genotypes describes an organism's complete set of genes, in this study was determined the homology among the samples of isolated bacteria from the mother-child pair, was reported the % of S. mutans genotypes isolated from the children.
|
Three months after the birth of the child.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2015
Primary Completion (Actual)
October 1, 2017
Study Completion (Actual)
December 1, 2017
Study Registration Dates
First Submitted
April 14, 2021
First Submitted That Met QC Criteria
April 27, 2021
First Posted (Actual)
May 3, 2021
Study Record Updates
Last Update Posted (Actual)
May 3, 2021
Last Update Submitted That Met QC Criteria
April 27, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Oral health promotion
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnant Women
-
National Institute of Neurosciences and Hospital...Directorate General of Health Services, BangladeshActive, not recruitingPregnant Women | Pregnant Women and Their OffspringBangladesh
-
TC Erciyes UniversityNot yet recruitingHypotension in Pregnant Women | Headache in Pregnant Women
-
Nantes University HospitalRecruiting
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruiting
-
Tokat Gaziosmanpasa UniversityOndokuz Mayıs UniversityNot yet recruiting
-
Myant Medical Corp.McMaster UniversityNot yet recruiting
-
Qianfoshan HospitalShandong Nursing AssociationRecruiting
-
Brigham and Women's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingPregnant WomenUnited States
-
Sultan Abdulhamid Han Training and Research Hospital...RecruitingPregnant WomenTurkey
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker CochinCompleted
Clinical Trials on Pregnant women to whom applied silane fluoride
-
Istanbul University - Cerrahpasa (IUC)RecruitingPreeclampsia | Healthy Lifestyle | Pregnancy; Renal DiseaseTurkey
-
University of Maryland, BaltimoreBill and Melinda Gates FoundationActive, not recruitingStillbirths and Infant MortalityMali
-
Kocaeli UniversityActive, not recruiting
-
Saglik Bilimleri Universitesi Gulhane Tip FakultesiCompletedChildbirth Fear, Anxiety,Birth PainTurkey
-
Sun Pharmaceutical Industries LimitedRecruitingSafety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With TildrakizumabPregnancy RelatedUnited States
-
Tarsus UniversityNot yet recruiting
-
Medical University of GdanskNot yet recruitingFear of Childbirth | Pregnancy-Related Anxiety (PrA)Poland
-
Karadeniz Technical UniversityCompletedSelf Efficacy | Perception, Self | Traumatic BirthTurkey (Türkiye)
-
Medical University of South CarolinaCompletedDepression | Pregnancy | Anxiety | Substance UseUnited States
-
Johns Hopkins Bloomberg School of Public HealthBill and Melinda Gates FoundationCompletedAdherence, PatientEthiopia